Gustavo Viani, Associate Professor at Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared on LinkedIn: about a recent paper by Han Xiao et al. published on JAMA Network:
“A New Era for Biliary Tract Cancers: ACCORD Trial Proves the Power of RT + Immunotherapy
Objective
- To assess whether camrelizumab + capecitabine + radiotherapy improves survival compared with observation after curative surgery for EHC and GBC.
Methods
- Design: Randomized clinical trial (ACCORD, 2020–2022)
- Population: 93 patients with resected EHC/GBC
- Intervention: Camrelizumab every 3 weeks → capecitabine with concurrent RT
- Control: Observation only
- Endpoints: Overall survival (OS, primary), recurrence-free survival (RFS), safety
Results
- OS at 3 years: 58% vs. 31% (HR 0.43; p=0.004)
- RFS at 3 years: 40% vs. 17% (HR 0.46; p<0.001)
- Well tolerated: no treatment-related deaths, only 13% with delay in immunotherapy
Clinical Impact
- This trial provides robust evidence that combining immunotherapy with adjuvant chemoradiation significantly increases survival in this challenging setting. It opens a new path for standardizing adjuvant therapy in resectable biliary tract cancers (EHC/GBC), historically lacking effective strategies.”
Title: Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
Authors: Han Xiao, Jiansong Ji, Shaoqiang Li, Jiaming Lai, Guangyan Wei, Jian Wu, Wei Chen, Wenxuan Xie, Shutong Wang, Liangliang Qiao, Jianfei Tu, Shunli Shen, Zhenwei Peng
More posts featuring Gustavo Viani.